Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Blood

Volumn 128, Issue 14, 2016, Pages 1821-1828

  Plesner, Torben ^a   Arkenau, Hendrik Tobias ^b   Gimsing, Peter ^c   Krejcik, Jakub ^a   Lemech, Charlotte ^b   Minnema, Monique C ^d   Lassen, Ulrik ^c   Laubach, Jacob P ^e   Palumbo, Antonio ^f   Lisby, Steen ^g   Basse, Linda ^g   Wang, Jianping ^h   Sasser, A Kate ⁱ   Guckert, Mary E ⁱ   De Boer, Carla ^j   Khokhar, Nushmia Z ⁱ   Yeh, Howard ⁱ   Clemens, Pamela L ⁱ   Ahmadi, Tahamtan ⁱ   Lokhorst, Henk M ^k   Richardson, Paul G ^e   more..

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TURIN   (Italy)

^g Genmab   (Denmark)

^h LLC   (United States)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^j Janssen Biologics   (Netherlands)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DARATUMUMAB; DEXAMETHASONE; LENALIDOMIDE; LIVER ENZYME; PROTEASOME INHIBITOR; THALIDOMIDE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC RHINITIS; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BRONCHITIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION; INFESTATION; INFUSION RELATED REACTION; KIDNEY DYSFUNCTION; LUNG EMBOLISM; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DEMOGRAPHY; DISEASE FREE SURVIVAL; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEMOGRAPHY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84990242886     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-07-726729     Document Type: Article

References (30)

1. Meadows JP, Mark TM. Management of double-refractory multiple myeloma. Curr Hematol Malig Rep. 2013;8(4):253-260.
2. Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014;7(1):97-111.
3. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101-119.
4. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
5. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311-321.
6. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 [abstract]. Blood. 2014;124(21). Abstract 3474.
7. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482-488.
8. Santonocito AM, Consoli U, Bagnato S, et al. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res. 2004;28(5):469-477.
9. + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394.
10. van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284-290.
11. Boxhammer R, Steidl S, Endell J. Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide [abstract]. Haematologica. 2015;100(s1):247. Abstract P636.
12. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219.
13. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
14. Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37-44.
15. Mateos MV, Moreau P, Comenzo R, et al. An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma [abstract]. Haematologica. 2015;100(s1):84. Abstract 275.
16. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf.
17. Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
18. McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54(6):1095-1104.
19. Durie BG, Miguel JF, Blade J, Rajkumar SV. Clarification of the definition of complete response in multiple myeloma. Leukemia. 2015;29(12):2416-2417.
20. Xu XS, Yan X, Puchalski T, et al. Understanding the dose regimen for daratumumab in patients with relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs): a quantitative pharmacologic perspective [abstract]. Blood. 2015;126(23). Abstract 4254.
21. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147-2152.
22. Dimopoulos M, Spencer A, Attal M, et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-2132.
23. Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-2142.
24. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545-1554.
25. Chari A, Satta T, Tayal A, et al. Outcomes and management of red blood cell transfusions in mutliple myeloma patients treated with daratumumab [abstract]. Blood. 2015;126(23). Abstract 3571.
26. De Vooght KM, Oostendorp M, van Solinge WW. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing [published online ahead of print 6 July 2016]. Curr Opin Hematol. doi:10.1097/MOH.0000000000000276.
27. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811-821.
28. van der Veer MS, de Weers M, van Kessel B, et al. Improved myeloma targeting by combination of the human anti-CD38 antibody daratumumab with lenalidomide and bortezomib [abstract]. Blood. 2010;116(21). Abstract 3030.
29. van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.
30. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiplemyeloma. N Engl J Med. 2016. In press.